These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 18158)

  • 1. Bufuralol, a new beta-adrenoceptor blocking agent. Part 1: synthesis and structure-activity studies in a series of benzofuran-2-ethanolamines.
    Fothergill GA; Osbond JM; Wickens JC
    Arzneimittelforschung; 1977; 27(5):978-81. PubMed ID: 18158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bufuralol, a new beta-adrenoceptor blocking agent in a series of benzofuran-2-ethanolamines. Part 2: pharmacology.
    Hamilton TC; Parkes MW
    Arzneimittelforschung; 1977 Jul; 27(7):1410-7. PubMed ID: 20114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bufuralol, a new beta-adrenoceptor blocking agent.
    Fothergill GA; Francis RJ; Hamilton TC; Osbond JM; Parkes MW
    Experientia; 1975 Nov; 31(11):1322-3. PubMed ID: 1287
    [No Abstract]   [Full Text] [Related]  

  • 4. Beta-adrenoceptor activity of the stereoisomers of the bufuralol alcohol and ketone metabolites.
    Machin PJ; Hurst DN; Osbond JM
    J Med Chem; 1985 Nov; 28(11):1648-51. PubMed ID: 2866246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arylethanolamines derived from salicylamide with alpha- and beta-adrenoceptor blocking activities. Preparation of labetalol, its enantiomers, and related salicylamides.
    Clifton JE; Collins I; Hallett P; Hartley D; Lunts LH; Wicks PD
    J Med Chem; 1982 Jun; 25(6):670-9. PubMed ID: 6124636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-adrenergic blocking agents. 19. 1-Phenyl-2-[[(substituted-amido)alkyl]amino]ethanols.
    Large MS; Smith LH
    J Med Chem; 1980 Feb; 23(2):112-7. PubMed ID: 6102152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decrease of peripheral resistance after acute intravenous application of a new beta-receptor blocking agents, bufuralol HCl.
    Magometschnigg D; Bonelli J; Hitzenberger G; Kaik G; Korn A
    Int J Clin Pharmacol Biopharm; 1978 Feb; 16(2):54-8. PubMed ID: 24595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preparation and beta adrenolytic activity of some derivatives of naphthol-[2,1-b]furan].
    Giovanninetti G; Garuti L; Chiarini A; Gaggi R
    Farmaco Sci; 1981 Feb; 36(2):94-101. PubMed ID: 6112160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enantioselective and diastereoselective hydroxylation of bufuralol. Absolute configuration of the 7-(1-hydroxyethyl)-2-[1-hydroxy-2-(tert-butylamino)ethyl]benzofurans, the benzylic hydroxylation metabolites.
    Weerawarna SA; Geisshüsler SM; Murthy SS; Nelson WL
    J Med Chem; 1991 Oct; 34(10):3091-7. PubMed ID: 1681107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of further amino-halogen-substituted phenyl-aminoethanols.
    Krüger G; Keck J; Noll K; Pieper H
    Arzneimittelforschung; 1984; 34(11A):1612-24. PubMed ID: 6152154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soft drugs. 12. Design, synthesis, and evaluation of soft bufuralol analogues.
    Hwang SK; Juhasz A; Yoon SH; Bodor N
    J Med Chem; 2000 Apr; 43(8):1525-32. PubMed ID: 10780909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adrenergic receptor agonists. Benzofuranylethanolamines.
    Lövgren K; Hedberg A; Nilsson JL
    J Med Chem; 1980 Jun; 23(6):624-7. PubMed ID: 6104731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic characterization of bufuralol-HCl and pindolol based on the competitive effects of isoproterenol.
    Magometschnigg D; Bonelli J; Kaik G
    Int J Clin Pharmacol Biopharm; 1979 Nov; 17(11):429-32. PubMed ID: 41815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Methoxyphenylethanolamines, potential beta-adrenergic blocking agents.
    Williams LR; Lap BV; Lim CH; Temple DM; Easson PA; Letts GL
    J Med Chem; 1978 Oct; 21(10):1081-4. PubMed ID: 31474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Naphthofuran derivatives with potential beta-adrenolytic activity].
    Garuti L; Ferranti A; Giovanninetti G; Gaggi R
    Farmaco Sci; 1983 Jul; 38(7):527-32. PubMed ID: 6137412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of bufuralol, a beta-adrenoceptor antagonist with predominant beta 2-adrenoceptor agonistic activity, in the cat and the dog.
    Blaber LC; Burden DT; Eigenmann R; Gerold M
    J Cardiovasc Pharmacol; 1984; 6(1):165-75. PubMed ID: 6199600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. beta-Adrenoceptor blocking activity of halogenated thienylethanolamine derivatives.
    Conde S; Corral C; Madroñero R; Alvarez-Insúa AS; Fernámdez-Tomé MP; Río J; Santos M
    J Med Chem; 1977 Jul; 20(7):970-4. PubMed ID: 17752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute hemodynamic effects of bufuralol: a beta-adrenoceptor blocking drug with vasodilatory effects.
    Pfisterer M; Burckhardt D; Bühler FR; Burkart F
    J Cardiovasc Pharmacol; 1984; 6(3):417-22. PubMed ID: 6202966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.
    Dayer P; Balant L; Kupfer A; Striberni R; Leemann T
    Eur J Clin Pharmacol; 1985; 28(3):317-20. PubMed ID: 2861095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of procaterol derivative having a piperidylmethanol group and its beta-adrenoceptor stimulant activities.
    Yoshizaki S; Tamada S; Umezato M; Yabuuchi Y
    Chem Pharm Bull (Tokyo); 1989 Dec; 37(12):3403-4. PubMed ID: 2576644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.